Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Tronox plunges as creditors reportedly engage restructuring advisors (SeekingAlpha) +++ TRONOX Aktie -11,61%

Foren & Soziale Netzwerke zur MODERNA Aktie

 >MODERNA Aktienkurs 
186.12 EUR    -5.0%    (TradegateBSX)
Ask: 186.54 EUR / 300 Stück
Bid: 186.12 EUR / 300 Stück
Tagesumsatz: 12493 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
MODERNA Aktie über LYNX handeln
>MODERNA Performance
1 Woche: -18,6%
1 Monat: +1,1%
3 Monate: +257,2%
6 Monate: +364,4%
1 Jahr: +816,8%
laufendes Jahr: +634,3%
>MODERNA Aktie
Name:  MODERNA INC. DL-,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US60770K1079 / A2N9D9
Symbol/ Ticker:  0QF (Frankfurt) / MRNA (NASDAQ)
Kürzel:  FRA:0QF, ETR:0QF, 0QF:GR, NASDAQ:MRNA
Index:  S&P500, Nasdaq100
Profil:  Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, r..
>Volltext..
Marktkapitalisierung:  81999.06 Mio. EUR
Unternehmenswert:  81165.12 Mio. EUR
Umsatz:  2290.85 Mio. EUR
EBITDA:  -2425.13 Mio. EUR
Nettogewinn:  -2530.37 Mio. EUR
Gewinn je Aktie:  -6.41 EUR
Schulden:  3836.84 Mio. EUR
Liquide Mittel:  1084.19 Mio. EUR
Operativer Cashflow:  -1619.47 Mio. EUR
Bargeldquote:  2.55
Umsatzwachstum:  17.18%
Gewinnwachstum:  7.29%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  MODERNA
Letzte Datenerhebung:  17.11.26
>MODERNA Kennzahlen
Aktien/ Unternehmen:
Aktien: 404.62 Mio. St.
Frei handelbar: 91.48%
Rückkaufquote: -0.21%
Mitarbeiter: 4700
Umsatz/Mitarb.: 0.38 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -30.76%
Bewertung:
KGV: -
KGV lG: -
KUV: 39.32
KBV: 13.6
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 17.82%
Gewinnmarge: -110.46%
Operative Marge: -116.04%
Managementeffizenz:
Gesamtkaprendite: -21.79%
Eigenkaprendite: -34.5%
>MODERNA Peer Group
 
13.11.26 - 17:12
MODERNA at 225$ OVERBOUGHT see it drop to 100's and below. (TradingView)
 
NASDAQ:MRNA Massive Breakout, but Is a Major Correction Coming? Quick Overview Moderna looks extremely overbought on the daily, weekly, and monthly timeframes. I believe a major correction toward the $100s and below is likely. The $60s or even lower could be possible if the $80–$100 support zone don't hold, which represents the previous weekly/monthly bull flag breakout, fails to hold. I wouldn't even consider buying this stock at $225. It has been rising for approximately 17 consecutive months without any significant drop. In contrast, starting in May 2024, it declined for roughly 12 consecutive months before marking a bottom. In my experience, when a stock trends in one direction for 10+ months, the probability of a significant reversal or pullback increases. ---Daily Timeframe--- MRNA is currently trading inside what I see as a potential bear flag. Once it loses $210, I believe that could mark the beginning of the major correction I'm anticipating. On the daily timeframe, there was a massive bulli
09.11.26 - 18:48
Piper_Sandler: buy Moderna Inc. (Sharewise)
 
Kursziel: 273.28 €
08.11.26 - 08:24
mixitrader: buy Moderna Inc. (Sharewise)
 
Kursziel: 230.0 €
26.10.26 - 15:18
Piper_Sandler: buy Moderna Inc. (Sharewise)
 
Kursziel: 204.953 €
26.10.26 - 13:54
kostojunior: sell Moderna Inc. (Sharewise)
 
Kursziel: -
24.10.26 - 08:06
mixitrader: buy Moderna Inc. (Sharewise)
 
Kursziel: 180.0 €
20.10.26 - 20:00
10/20/26 - $mrna - genocidal juggernaut (TradingView)
 
10/20/26 :: VROCKSTAR :: NASDAQ:MRNA genocidal juggernaut - what could be more profitable than the USSA buying your cancer causing juice and then the "insurance" companies paying you for your cancer "curing" juice - meet moderna, everyone's favorite insider trading, politician infested, death-cult-loving pharmakeia companies - and heading into halloween, the most perverted "holiday" that you should reconsider participating in - but i digress - let's stick to the facts - the facts are that this press-release-is-our-product company makes no cash flows. zero. - trades at 35x next year's sales (looks like NASDAQ:CRWD lol!) but grows 15% and we're expected to believe "the best is yet to come" and they'll grow 40% the year after that - run by a less trustworthy management team than theranos - so yeah, hard to value a company that made money once, requiring a global pandemic, and then "claims" to cure cancer and at some point "trust me bro" we're going to generate cash flows again - and look at those insider b
19.10.26 - 10:03
Moderna, Inc. (MRNA) Tradespoon – Long Setup $219.98 (TradingView)
 
Tradespoon model shows a long bias for NASDAQ:MRNA . Predicted range: $206.11–$236.50. Trend: -2.41% (near-term pullback amid volatility ahead of key clinical data). NASDAQ:MRNA
22.09.26 - 17:06
MRNA -major short squeeze. Here's how I think this will play out (TradingView)
 
NASDAQ:MRNA — major short squeeze still going on. Here's how I think this will play out. ? #MRNA #Moderna #ShortSqueeze #Stocks #Trading #StockMarket #TechnicalAnalysis #PriceAction #DayTrading #Investing
14.09.26 - 17:54
MRNA - Moderna, Inc. (TradingView)
 
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
01.09.26 - 09:09
MRNA: Expecting More Upside (TradingView)
 
Moderna's recent rally is driven by two strong clinical milestones: the personalized mRNA melanoma vaccine developed with Merck hit its Phase 3 goals, and the seasonal flu shot (mFLUSIVA) received FDA approval. Analysts are treating the melanoma result as a landmark validation of Moderna's oncology pipeline, and price targets have been revised sharply higher. The technical picture confirms the fundamental story. The broader trend structure supports further upside expansion toward the 250–310 resistance zone over the coming months. Chart: https://www.tradingview.com/x/4xAYWVMR/ We keep this scenario active as long as price holds above the 117–103 support area. We plan to enter once a clean risk/reward setup appears.
20.08.26 - 08:33
MRNA: Moderna Is The Hero AGAIN! (TradingView)
 
Short-Term Outlook After an almost 200% move in a stock in a single day, making a definitive prediction about whether the bullish move will see follow-through—or whether a short-term top is already in place and an immediate corrective wave will follow—would be little more than fortune-telling. History was made yesterday; let's call it what it is. We're pleased to have correctly anticipated the move—not to this extent, obviously, but the direction and its imminence were clear. For short-term targets, however, we'll need to step back and closely monitor the market's reaction over the next few trading sessions. Long-Term Outlook The weekly chart suggests the stock should see significant long-term gains and eventually break through resistance at $497.49, which is the current all-time high.
31.07.26 - 16:15
Moderna: Modest Gains (TradingView)
 
Moderna shares traded mostly sideways over the past week, but today we're seeing renewed upward movement. Our primary view remains that MRNA is likely to see further declines in the near term. After a low well above support at $22.32, however, a recovery should unfold, pushing the stock up to and above resistance at $85.60. If the stock were to fall below support at $22.32 in the near future, we would expect to see a lower low before the anticipated upward move resumes (probability: 20%).
10.07.26 - 13:18
Another Opportunity, The Same Process in MRNA (TradingView)
 
https://www.tradingview.com/x/gmayCOKe/ After entering **PANW**, I continued monitoring several other stocks that had already caught my attention. A number of them were demonstrating strong relative strength and, from my perspective, signs of sustained institutional participation. Among those names, **MRNA** was the next asset to present a valid entry according to my trading plan. The signal appeared very close to the market close, and my order was filled in the final minutes of the session. Because of the timing, I didn't have the opportunity to reduce the trade's risk by moving my stop-loss to **break-even** before the market closed. As I write this before today's opening, MRNA is trading **higher in the pre-market**. I don't interpret that as a prediction of what will happen next, nor do I assume the trade will become profitable because of it. What matters to me is much simpler. If the opening provides enough strength, I'll have the opportunity to move my stop-loss to **break-even**, making the posi
11.05.26 - 16:03
"Der Aktionär" steigt ein....morgen in (Ariva)
 
der online Ausgabe nachlesbar -eintracht67
11.05.26 - 10:30
Moderna im Hantavirus-Fieber! (Ariva)
 
Ein lokaler Ausbruch des Hantavirus auf einem Kreuzfahrtschiff treibt die Moderna-Aktie (MRNA) an. https://traderzeitung.de/boerse/hot-news/moderna-im-hantavirus-fieber-zwischen-spekulativem-kurssprung-und-hart-167994.html -micha1
08.05.26 - 21:27
ad-hoc-news.: Aktie im Aufwind (Ariva)
 
Moderna Inc Aktie (US60770K1079): Quartalsumsatz deutlich über Guidance, Aktie im AufwindDie Aktie von Moderna Inc (ISIN: US60770K1079, Ticker: MRNA) notiert am 08.05.2026 auf dem US-amerikanischen Markt bei rund 48,70 US-Dollar ... -micha1
08.05.26 - 21:18
Hantavirus Schlagzeilen treiben Impfstoff Aktie an (Ariva)
 
Medienberichten zufolge arbeitet Moderna seit dem September 2023 mit der Korea University an einem Hantavirus-Impfstoff. Laut The Hill befindet sich die Forschung noch in einem frühen Stadium. "Moderna hat in Zusammenarbeit mit dem U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) präklinische Forschungen zu Hantaviren durchgeführt, was die anhaltenden regionalen Auswirkungen dieser Krankheitserreger widerspiegelt“, zitiert die US-amerikanische Zeitung einen Unternehmenssprecher.https://de.investing.com/news/stock-market-news/hantavirusforschung-treibt-modernaaktie-um-16--an-93CH-3472484 -micha1
26.04.26 - 23:48
DerAlmanach100000: buy Moderna Inc. (Sharewise)
 
Kursziel: -
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Ehe ist die einzige wahre Form von Leibeigenschaft, die unser Gesetz noch kennt. Es gibt, außer den Herrinnen des Hauses, keine Sklaven mehr. - John Stuart Mill
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!